Yu Aihara

Yu Aihara

Auto-generated profile, based on publicly available information

Yu Aihara

Department of Pediatrics, Tohoku University Graduate School of Medicine, Sendai, Japan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Brain and Development
Verified
Journal Article
Closed access
SISota Iwafuchi
Sota Iwafuchi
AKAtsuo Kikuchi
Atsuo Kikuchi
WEWakaba Endo
Wakaba Endo
TITakehiko Inui
Takehiko Inui
YAYu Aihara
Yu Aihara
SKShigeo Kure
Shigeo Kure

31 December 2021 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
YKYu Katata
Yu Katata
SUSaki Uneoka
Saki Uneoka
NSNaoya Saijyo
Naoya Saijyo
YAYu Aihara
Yu Aihara
TMTakamitsu Miyazoe
Takamitsu Miyazoe
SKShigeo Kure
Shigeo Kure

12 July 2023 in Brain and Development
Verified
Journal Article
Closed access
YOYukimune Okubo
Yukimune Okubo
MSMoriei Shibuya
Moriei Shibuya
HNHaruhiko Nakamura
Haruhiko Nakamura
AKAritomo Kawashima
Aritomo Kawashima
KKKaori Kodama
Kaori Kodama
KHKazuhiro Haginoya
Kazuhiro Haginoya

15 December 2025 in Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
YWYoichi Wada
Yoichi Wada
YAYu Aihara
Yu Aihara
YMYasuko Mikami-Saito
Yasuko Mikami-Saito
TSTomohisa Suzuki
Tomohisa Suzuki
RFRyoji Fujiki
Ryoji Fujiki
SKShigeo Kure
Shigeo Kure
Galactose, a monosaccharide, plays diverse biological roles in energy production, especially in the glycolysis and glycosylation of proteins and lipids. Galactose metabolism is mediated by the Leloir pathway, which comprises four key enzymes. Following lactose hydrolysis, galactose mutarotase (GALM) catalyzes the anomerization of β-D-galactose to α-D-galactose, providing a substrate for the downstream pathway. In 2019, GALM deficiency was defined as the fourth type of galactosemia. Affected individuals may develop cataracts similar to those observed in individuals with galactokinase deficiency, disrupting the subsequent steps in the Leloir pathway. However, cataracts generally occur less frequently and tend to be milder in patients with GALM deficiency, likely because of the partial compensation provided by spontaneous galactose mutarotation in aqueous solutions. Because lactose, the primary dietary source of galactose, is the predominant carbohydrate consumed until weaning, the timely initiation of lactose restriction can prevent or even reverse cataract formation. To date, other complications or adverse events, including those in heterozygous carriers of GALM variants, have not been clearly demonstrated. This review aims to synthesize current knowledge and findings of GALM deficiency on molecular mechanisms, clinical presentation, diagnostic approaches, carrier risk, and dietary management, with particular emphasis on cataract prevention and reversibility through early lactose restriction. By consolidating available evidence, we propose future research directions, with broader implications for newborn screening programs, clinical decision-making, and a deeper understanding of galactose metabolism.